EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma

Zhiwei Li, Xiaona Fan, Dan Jiang, Qingwei Li, Chao Liu, Dan Wang, Na Li, Hengzhen Li, Zhuo Chen, Hongzhen Tang, Changjie Lou, Haitao Xu und 8 weitere

The Oncologist · 2024

DOI: 10.1093/oncolo/oyae207 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2024. Verfasst von Zhiwei Li und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China. Hauptthemen laut MEDLINE: Albumins, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal, Deoxycytidine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Harbin Medical University Cancer Hospital, Major Research and Development Program of Heilongjiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alternating sequential administration of drugs may be a promising approach to overcome chemotherapy resistance in advanced pancreatic ductal adenocarcinoma (PDAC).

Methods

This study was an open-label, single-arm, and prospective trial included patients with untreated advanced PDAC. They received 2 cycles of NS regimen (nab-paclitaxel:125 mg/m2, intravenously injected on days 1 and 8, plus S-1:40-60 mg, orally twice per day for 1-14 days) followed by 2 cycles of GemOx regimen (gemcitabine, intravenously injected on days 1 and 8, and oxaliplatin: 130 mg/m2, intravenously injected on day 1). The primary efficacy endpoint was a progression-free survival rate at 6 months (PFSR-6m). The secondary efficacy endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). Specific mRNA transcripts were used to explore survival associated genes.

Results

Forty-two patients received a minimum of one treatment cycle, and of these, 30 patients completed one alternating treatment consisting of 4 cycles. The PFSR-6m was 71% (95% CI = 58%-87%). The median PFS and OS were 6.53 months (95% CI = 6.03-8.43) and 11.4 months (95% CI = 9.8-14.4), respectively. Common grades 3-4 hematological AEs included neutropenia 30.9%, leukopenia 26.2%, anemia 2.4%, and thrombocytopenia in 11.9%. Patients with OS > 10 months showed high expression of HLA-DQA2 while melanoma-associated antigen genes (MAGE) were notably upregulated in patients with OS < 10 months.

Conclusion

The alternating sequential administration of the NS and GemOx regimens may be a novel approach for first-line chemotherapy in patients with advanced PDAC requiring further study (ClinicalTrials.gov Identifier: ChiCTR1900024867).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbuminsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalDeoxycytidineDrug CombinationsGemcitabineOxaliplatinOxonic AcidPaclitaxelPancreatic NeoplasmsTegafurAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesOrganoplatinum Compounds

Stichwörter der Autor:innen

GemOXNab-paclitaxel plus S-1pancreatic ductal adenocarcinomaphase IIsequential treatment

Substanzen

130-nm albumin-bound paclitaxelAlbuminsDeoxycytidineDrug CombinationsGemcitabineOxaliplatinOxonic AcidPaclitaxelS 1 (combination)Tegafur

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China.
  • Shenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, People's Republic of China.
  • Department of Hepatobiliary and Pancreatic Surgery, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China.

ORCID-Profile: Yanqiao Zhang

Förderung

  • National Natural Science Foundation of China
  • Harbin Medical University Cancer Hospital
  • Major Research and Development Program of Heilongjiang Province

Zitieren

APA

Li, Z., Fan, X., Jiang, D., Li, Q., Liu, C., Wang, D., Li, N., Li, H., Chen, Z., Tang, H., Lou, C., Xu, H., Zhan, C., Dong, Y., Ma, Z., Wang, G., Zhang, C., Lu, H., Zheng, T., & Zhang, Y. (2024). Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyae207

Vancouver

Li Z, Fan X, Jiang D, Li Q, Liu C, Wang D, et al. Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma. The Oncologist. 2024. doi:10.1093/oncolo/oyae207

BibTeX
@article{Li2024,
  author = {Li, Zhiwei and Fan, Xiaona and Jiang, Dan and Li, Qingwei and Liu, Chao and Wang, Dan and Li, Na and Li, Hengzhen and Chen, Zhuo and Tang, Hongzhen and Lou, Changjie and Xu, Haitao and Zhan, Chao and Dong, Yuandi and Ma, Zhigang and Wang, Guangyu and Zhang, Chunhui and Lu, Haibo and Zheng, Tongsen and Zhang, Yanqiao},
  title = {Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyae207}
}
Kostenlos starten →